Get all your news in one place.
100’s of premium titles.
One app.
Start reading
The Street
The Street
Business
Dan Weil

Cathie Wood Watch: Ark Sells Electric Vehicle Maker Again

Investment heavyweight Cathie Wood, chief executive of Ark Investment Management, sold shares of a major electric vehicle maker for the third consecutive day Thursday.

Ark also unloaded one of the top social media platforms. In addition, it bought biotechnology stocks, a financial exchange stock and a robotics stock. (All valuations listed below are as of Thursday’s close).

Ark funds sold 37,551 shares of Tesla (TSLA), valued at $40.5 million. Wood has said in the past that her sales of Tesla just represent profit-taking and that she remains bullish for the long term. Tesla is the biggest holding in Wood’s flagship Ark Innovation ETF (ARKK).

Ark Fintech Innovation ETF (ARKF) unloaded 78,751 shares of Twitter (TWTR), valued at $3 million. Ark Fintech dumped 23,284 shares of financial exchange company Intercontinental Exchange (ICE), valued at $3.1 million

These are the other three stocks for which Ark sold the highest amount of shares Thursday. Ark Innovation bought 3.85 million shares of biotechnology company Ginkgo Bioworks  (DNA) , valued at $15.5 million.

Ark funds snatched 1.27 million shares of robotics company UiPath (PATH), valued at $27.4 million. Ark Genomic Revolution ETF (ARKG) snapped up 503,831 shares of biotechnology company SomaLogic  (SLGC) , valued at $4 million.

On Wednesday, Wood bought a drug-discovery-technology stock, again bulked up on Coinbase  (COIN) , the country’s largest cryptocurrency exchange and again sold shares of Tesla. She also continued her buying of 3D-printing stocks.

Ark funds purchased 496,322 shares of Twist Bioscience (TWST), valued at $24.9 million as of Wednesday’s close.

Twist Bio, says on its investor-relations page that the core of its platform "is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by 'writing' DNA on a silicon chip.

"We are leveraging our unique technology platform to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for NGS sample preparation, and antibody libraries for drug discovery and development."

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.